MARKET

DRRX

DRRX

DURECT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.751
+0.031
+1.77%
Opening 10:15 11/24 EST
OPEN
1.720
PREV CLOSE
1.720
HIGH
1.780
LOW
1.720
VOLUME
223.18K
TURNOVER
--
52 WEEK HIGH
3.949
52 WEEK LOW
0.9502
MARKET CAP
355.67M
P/E (TTM)
-35.1506
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
DURECT share slumps on Q3 miss, welcomes new CMO
DURECT ([[DRRX]] -7.6%) Q3 total revenue $2.7M, compares to $10.8M last year figure.Net loss was $9.3M.At September 30, 2020, cash and investments were $49.8M, compared to cash and investments of $51.3M
Seekingalpha · 11/03 19:26
Durect (DRRX) Reports Q3 Loss, Lags Revenue Estimates
Durect (DRRX) delivered earnings and revenue surprises of -25.00% and -23.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/02 23:15
Durect EPS misses by $0.01, misses on revenue
Durect (DRRX): Q3 GAAP EPS of -$0.05 misses by $0.01.Revenue of $2.68M (-75.1% Y/Y) misses by $1.29M.Cash and investments were $49.8M.Press Release
Seekingalpha · 11/02 21:22
Durect Q3 EPS $(0.05) Misses $(0.04) Estimate, Sales $2.70M Miss $3.56M Estimate
Durect (NASDAQ:DRRX) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 400 percent decrease over losses of $(0.01) per share from the same
Benzinga · 11/02 21:11
DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer
DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on the development of treatments for acute organ injury and chronic liver diseases, today announced it has appointed Norman Sussman, M.D. as its Chief Medical Officer, effective immediately. In this new role, Dr. Sussman will oversee the clinical development of DURECT's pipeline including multiple indications for its lead investigational drug candidate DUR-928.
PR Newswire · 11/02 21:02
DURECT Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 2, 2020 / DURECT Corp.
ACCESSWIRE · 11/02 19:30
Forget Bargain Hunting: Play 5 Stocks With Rising P/E
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
Zacks · 11/02 12:35
DURECT Corporation To Participate In ROTH Capital Partners Healthcare Event 'Covid-19 Therapeutics in Development' Oct. 28
CUPERTINO, Calif., Oct. 26, 2020 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it will partipate in the ROTH Capital Healthcare Event, "Covid-19 Therapeutics in
Benzinga · 10/26 20:31
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DRRX. Analyze the recent business situations of DURECT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DRRX stock price target is 6.17 with a high estimate of 7.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 155
Institutional Holdings: 140.09M
% Owned: 68.95%
Shares Outstanding: 203.18M
TypeInstitutionsShares
Increased
27
1.80M
New
19
224.87K
Decreased
40
4.88M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.35%
Pharmaceuticals & Medical Research
+0.22%
Key Executives
Chairman/Independent Director
David Hoffmann
President/Chief Executive Officer/Director
James Brown
Chief Financial Officer
Michael Arenberg
Senior Vice President
Judy Joice
Other
Norman Sussman
Independent Director
Simon Benito
Independent Director
Terrence Blaschke
Independent Director
Gail Farfel
Independent Director
Armand Neukermans
Independent Director
Judith Robertson
Independent Director
Jon Saxe
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DRRX
Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of DURECT Corporation stock information, including NASDAQ:DRRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DRRX stock methods without spending real money on the virtual paper trading platform.